Anti-IP6K2 Antibody

Mouse Monoclonal Antibody specific to IP6K2

Product Specifications

CAS Number

9007-83-4

Product Name Alternative

InsP6 kinase 2, InsP6K2, EC 2.7.4.-, P(i-uptake stimulator, PiUS

Gene Name

IP6K2

Gene ID

51447

NCBI Gene ID

UniProt

Q9UHH9

Accession Number

NP_001005909

Cellular Locus

Nucleus

Host

Mouse

Reactivity

Human

Immunogen

Full-length recombinant human IP6K2.

Target Antigen

Inositol hexakisphosphate kinase 2

Target

IP6K2

Clonality

Monoclonal

Isotype

IgG2b

Type

Antibody

Applications

Field of Research

Apoptosis

Purification Method

Purified by Protein G affinity chromatography

Concentration

Lot Specific

Dilution

Dilute in PBS or medium which is identical to that used in the assay system.

Format

Purified

Form

Liquid

Buffer

Phosphate Buffered Saline

Function

Converts inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5). {PubMed:10574768, PubMed:30624931}.

Additionnal Information

Immunoblotting: A band of ~49 kDa is detected. User should determine optimal concentrations for their application. <br><br>Positive control: purified human IP6K2 or NIH-OVCAR-3 cells after treatment with interferon (IFN)-b.

Storage Conditions

This antibody is stable for at least one (1) year at -20°C.

Specificity

This antibody recognizes human IP6K2.

Formulation

PBS, pH 7.4.

Buffer pH

pH 7.4

Target Background

Inositol hexakisphosphate kinase 2 (IP6K2) catalyzes the production of diphosphoinositol pentakisphosphate (IP7) and has a role as a proapoptotic gene sensitizing cancer cells to apoptosis by cell stressors and anticancer drugs all of which depend on IP6K2 catalytic activity. IP6K2 is located in the 3p21.31 chromosomal region, which often undergoes allele loss in a variety of human cancers. Some heat shock proteins, especially Hsp90, can be antiapoptotic and the targets of anticancer drugs. Hsp90 binds IP6K2 and inhibits its catalytic activity. Drugs and selective mutations that abolish HSP90-IP6K2 binding elicit activation of IP6K2, leading to cell death. Thus, the prosurvival actions of HSP90 reflect the inhibition of IP6K2, suggesting that selectively blocking this interaction could provide effective and safer modes of chemotherapy.